The FDA has withdrawn its accelerated approval of Krazati combined with Erbitux for adults with KRAS G12C-mutated colorectal cancer that is locally advanced or has spread to other parts of the body.
Press Release|Articles|September 17, 2026
Alliance Appoints New Members to Board of Directors
Listen
0:00 / 0:00
Key Takeaways
- Ross Cohen brings Goldman Sachs biotech/pharma dealmaking expertise and a family-driven commitment following a March 2024 early-onset colon cancer diagnosis in his wife, emphasizing awareness, advocacy, and innovation.
- Lenny Mendonça contributes extensive cross-sector governance and public-policy experience, including senior McKinsey leadership and advisory roles in California state government and major infrastructure oversight.
The Colorectal Cancer Alliance (Alliance), the nation’s leading nonprofit dedicated to ending colorectal cancer, is pleased to announce the appointment of four new members to its Board of Directors.
Advertisement
The Colorectal Cancer Alliance (Alliance), the nation’s leading nonprofit dedicated to ending colorectal cancer, is pleased to announce the appointment of four new members to its
"We're excited to welcome a talented group of new board members whose diverse expertise and insights will strengthen our work," said Michael Sapienza, CEO of the Colorectal Cancer Alliance. "Their passion and leadership will help drive meaningful progress for patients and families across the colorectal cancer community."
The new board members include:
- Ross Cohen is a Managing Director in the Healthcare Group of Goldman Sachs' Investment Banking Division, advising clients in biotechnology and pharmaceuticals. His wife, Siobhan, was diagnosed with early-onset colon cancer in March 2024, inspiring his commitment to advancing awareness, patient advocacy and treatment innovation.
- Lenny Mendonça is a Senior Partner Emeritus of McKinsey & Company and previously served as Chief Economic and Business Advisor to California Governor Gavin Newsom and Chair of the California High-Speed Rail Authority. He has served on numerous nonprofit and civic boards, and co-founded the Half Moon Bay Brewing Company and Inn at Mavericks with his wife Christine Mendonca.
- Cory Tull is a corporate partner and Deputy Office Managing Partner in the Washington, D.C. office of Latham & Watkins, focusing on mergers, acquisitions and complex business transactions. He became involved with the Alliance after losing his first wife, Corinne, to colorectal cancer in 2020 at age 39, and is devoted to reversing troubling trends in young-onset colorectal cancer.
- Peter Wright is a partner in McKinsey's Life Sciences practice based in Southern California, advising clients across biotech, biopharma and medtech. He works extensively in oncology as part of McKinsey Cancer Center where he leads research and convenes stakeholders on evolution of the U.S. oncology landscape and opportunities to address gaps in cancer care.
As the Alliance advances its strategic initiatives, including
The Colorectal Cancer Alliance looks forward to the insight and leadership these new members bring as the organization continues to expand its impact for all those affected by colorectal cancer.
To learn more about the Alliance's Board of Directors and read full member bios,
Advertisement
Related to this article
After cancer, taking time to rest and travel can create space to heal, reconnect and remember that life is about more than simply surviving.
Dr. Dina Khalaf explains the ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 trials and what patients with AML or MDS should ask before enrolling.
Children with diffuse midline glioma who took Keppra lived a median of 20.96 months, compared with 9.92 months for those who did not, a new study found.
A phase 1 trial treated 15 patients with breast cancer that spread to the spinal fluid using a vaccine made from their own immune cells. One patient is now more than three years from diagnosis.
Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
FDA approves an updated Ibtrozi label for locally advanced or metastatic ROS1-positive NSCLC, reflecting nearly four years of response data.
Gentle movement during cancer treatment can help maintain strength, mobility and balance. Follow Jennifer Tipton’s simple exercises to keep your body moving.
Advertisement
Advertisement